01 Oct 2017
Home
File List, RICO
1988 Steere says Lyme is like a B cell leukemia
Assoc Blogs-n-Webs:
TruthCures.org
badlymeattitude.com/
immune2lies.com/
researchfraud.com/
may12.org
meadvocacy.org/
truthbetoldx81
lymecryme
CrymeDiseaseNorway
crymedisease
theothersideofthestretcher
rjspiritualityandtuth
LymeTruthSite
JC-LilnkedIn
KD-Linkedin.com
LD-LinkedIn
JC-academia.edu
KD-academia.edu
CDC "SPIDER"
Fungal Exosomes Inhibit Apoptosis
IDSA:
"Vaccines serve the mfgs, not their victims"
RICO_filed_USDOJ
BlumenthalAntiTrust Lawsuit
Exosomes, Blebs
Spirochetal_Dementia
PDFs
CDC Admits Fraud, 2016
Dattwyler, 1988
Golightly, 1988
Dressler,
1994
BarbourFish, 1993
Dearborn,
1994
BarbourFishpdf.pdf
Pathogenic Fungi
Bush's warcrimes, Oct 2000
Trainer
170708 |
| |
Short Summary of failed
fungal vaccines and
immunosuppression caused by
LYMErix:
THE MECHANICS OF FUNGAL-ANTIGEN-RELATED IMMUNE
SUPPRESSION- Brought to you as a summary of the available
science.
1) Tolerance Induced by the Lipopeptide Pam3Cys
[OspA] Is Due to Ablation of IL-1R-Associated Kinase-11
"Although a
single ligation of TLRs induces responses such as TNF production,
repeated ligation will lead to a loss of response, i.e., the
cells become tolerant." http://www.jimmunol.org/cgi/content/full/173/4/2736
2) "Borrelia burgdorferi-Induced Tolerance as a Model of Persistence via
Immunosuppression" -
"In summary, we characterized tolerance induced
by B. burgdorferi, describing a model of desensitization
which might mirror the immunosuppression recently attributed to the
persistence of Borrelia in immunocompetent hosts." http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=12819085
3) Mycobacterium
tuberculosis LprG (Rv1411c): A Novel TLR-2 Ligand That Inhibits Human
Macrophage Class II MHC Antigen Processing1
http://www.jimmunol.org/cgi/content/full/173/4/2660
The Journal of Immunology, 2004, 173: 2660-2668. Copyright © 2004 by
The American Association of Immunologists
"Signaling
through TLR-2 by lipoproteins may represent a double-edged sword for host responses to chronic intracellular pathogens such as M. tuberculosis. Short-term signaling through TLR-2 activates macrophages and initiates acute inflammation that may help control initial infection. In contrast, prolonged
TLR-2 signaling in macrophages results in down-regulation of
certain critical immune functions, such as MHC-II Ag
processing. M. tuberculosis infects, survives, and
persists in macrophages. The ability of M. tuberculosis to
survive acute inflammation positions the bacilli to take
advantage, through secretion of lipoproteins such as LprG and
LpqH, of this
down-regulation of macrophage immune function."
4) Lipopolysaccharide Binding Protein Binds to Triacylated
and Diacylated Lipopeptides and Mediates Innate Immune Responses1
http://www.jimmunol.org/cgi/content/full/173/4/2683
"Lipoproteins and lipopeptides have been identified in a large
number
of microorganisms, the most prominent ones being mycobacteria, mycoplasms, and spirochetes. They have been found to exhibit
both a
strong innate inflammatory response in the host and an enduring
adaptive immune response in mammalian hosts (16).
The strong proinflammatory capacities of lipoproteins were first
described for outer surface proteins A and B of
Borrelia burgdorferi,
which are also highly immunogenic (17)
and have lately been the basis for a Lyme disease vaccine development
(18).
These compounds exhibit an triacylated lipid anchor structure
comprising an N-palmitoyl-S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-(R)-cysteinyl
(Pam3Cys) moiety at the N terminus (19),
a feature that was previously described for the Braun lipoprotein
from Escherichia coli (20).
Because the N-terminal Pam3Cys modification is essential for immunoactivation caused by lipoproteins of B. burgdorferi
as well as of another spirochete, Treponema pallidum (21),
subsequent studies investigating immune responses to spirochetes used
synthetic lipopeptides (22).
The Pam3Cys moiety was also reported to be present in
cytokine-inducing lipoproteins of Mycobacterium and Mycoplasma spp. (23,
24); thus,
it can be regarded as a highly conserved molecular motif among
different classes of bacteria. In Mycoplasma fermentans, the
presence of a macrophage stimulating lipopeptide, termed 2-kDa
macrophage-activating lipopeptide (MALP-2), was observed, being
stimulatory active at picomolar concentrations (25).
This compound, in contrast to the predominant lipopeptide structures
present in lipoproteins of E. coli, B. burgdorferi, and
mycobacteria, lacks the N-palmitoyl group, thus containing a
diacylated (Pam2Cys) lipid anchor structure at the N
terminus. Following studies revealed the presence of closely related
compounds in other Mycoplasma spp. (26).."
"Toll-like receptors (TLRs) 2 and 4 are
signal transducers for lipopolysaccharide, the major proinflammatory
constituent in the outer membrane of Gram-negative bacteria. We
observed that membrane lipoproteins/lipopeptides from Borrelia burgdorferi,
Treponema pallidum, and Mycoplasma fermentans
activated cells heterologously expressing TLR2 but not those
expressing TLR1 or TLR4. These TLR2-expressing cells were also
stimulated by living motile B. burgdorferi, suggesting that TLR2
recognition of lipoproteins is relevant to natural Borrelia
infection. Importantly, a TLR2 antibody inhibited bacterial
lipoprotein/lipopeptide-induced tumor necrosis factor release
from human peripheral blood mononuclear cells, and TLR2-null
Chinese hamster macrophages were insensitive to lipoprotein/lipopeptide
challenge. The data suggest a role for the native protein in
cellular activation by these ligands. In addition, TLR2-dependent
responses were seen using whole Mycobacterium avium and
Staphylococcus aureus, demonstrating that this receptor can
function as a signal transducer for a wide spectrum of bacterial products. We conclude that diverse pathogens activate cells through
TLR2 and propose that this molecule is a central pattern recognition
receptor in host immune responses to microbial
invasion."
http://www.jimmunol.org/cgi/content/full/173/4/2683
5)
http://www.jleukbio.org/cgi/content/full/75/3/460
It is interesting that in this Tg mouse model,
antigen-presenting cells (macrophages and dendritic and B cells)
rather than T cells provide the major source of elevated HIV-1
production. Furthermore, we have recently demonstrated that
known TLR agonists such as LPS, monosylated
phosphatidylinositol, CpG, and
S-[2,3-bis(palmitoyloxy)-(2-RS)-propyl]-N-palmitoyl-(R)-Cys-(S)-Ser-Lys4-OH,
trihydrochloride (Pam3Cys) stimulate increased levels
of HIV-1 transcripts as well as production of p24 (a
capsid protein encoded by the gag gene) by Tg spleen
cells in vitro [15
, 16
].
In the present report, we show that after tolerization with
TLR2, TLR4, or TLR9 ligands, Tg cells unexpectedly display
enhanced HIV-1 gene and protein expression after
restimulation in vitro despite dramatic reductions in
proinflammatory cytokine production. Moreover, Tg mice
tolerized in vivo with LPS or Pam3Cys show increased
levels of plasma p24, whereas TNF-
production is markedly diminished in the same animals.
This overexpression of HIV-1 genes following TLR
reprogramming may reflect a mechanism used by the virus
to escape the effects of microbial-induced tolerance during natural infection in vivo.
The induction of Toll-like receptor
tolerance enhances rather than suppresses HIV-1 gene expression in
transgenic mice.
Immunobiology Section, Laboratory of
Parasitic Diseases, National Institutes of Allergy and Infectious
Diseases, National Institutes of Health, Bethesda, MD 20982, USA.
abafica@niaid.nih.gov
Microbial-induced proinflammatory pathways
are thought to play a key role in the activation of human
immunodeficiency virus type 1 (HIV-1) gene expression. The induction
of Toll-like receptor (TLR) tolerance leads to a complex
reprogramming in the pattern of inflammatory gene expression and
down-modulates tumor necrosis factor alpha (TNF-alpha), interleukin
(IL)-1, and IL-6 production. Using transgenic (Tg) mice that
incorporate the entire HIV-1 genome, including the long-terminal
repeat, we have previously demonstrated that a number of different
TLR ligands induce HIV-1 gene expression in cultured splenocytes as
well as purified antigen-presenting cell populations. Here, we have
used this model to determine the effect of TLR-mediated tolerance as
an approach to inhibiting microbial-induced viral gene expression in
vivo. Unexpectedly, Tg splenocytes and macrophages, rendered
tolerant in vitro to TLR2, TLR4, and TLR9 ligands as assessed
by proinflammatory cytokine secretion and nuclear factor-kappaB
activation, showed enhanced HIV-1 p24 production. A similar
enhancement was observed in splenocytes tolerized and then
challenged with heterologous TLR ligands. Moreover, TLR2- and
TLR4-homotolerized mice demonstrated significantly increased plasma
p24 production in vivo despite lower levels of TNF-alpha.
Together, these results demonstrate that HIV-1 expression is
enhanced in TLR-reprogrammed host cells, possibly reflecting a
mechanism used by the virus to escape the effects of
microbial-induced tolerance during natural infection in vivo.
See? That's a major F-up, that might have been
investigated sooner, had the Yale Lyme crooks told the truth about
LYMErix in the mid-1990s when they were having their fake OspA
(Pam3Cys) trials, for which the changed the diagnostic standard for
Lyme.
This is in addition to the
fact that OspA was never shown to prevent Lyme in lab animals.
That's 5 reports that showed OspA failed in animals, 3
reports that showed fungal antigens failed in tuberculosis
vaccines, plus the 8 reports you see here.
6) AUGUST, 2008:
Human immunodeficiency virus infection alters tumor necrosis factor
alpha production via Toll-like receptor-dependent pathways in alveolar
macrophages and U1 cells.
http://www.ncbi.nlm.nih.gov/pubmed/18524817
Center for HIV/AIDS Care and Research, Boston
University School of Medicine, Boston, MA 02118-2393, USA. mnicol@bu.edu
Human immunodeficiency virus (HIV)-positive persons are
predisposed to pulmonary infections, even after receiving effective highly
active antiretroviral therapy. The reasons for this are unclear but may
involve changes in innate immune function. HIV type 1 infection of
macrophages impairs effector functions, including cytokine production. We
observed decreased constitutive tumor necrosis factor alpha (TNF-alpha)
concentrations and increased soluble tumor necrosis factor receptor type II
(sTNFRII) in bronchoalveolar lavage fluid samples from HIV-positive subjects
compared to healthy controls. Moreover, net proinflammatory TNF-alpha
activity, as measured by the TNF-alpha/sTNFRII ratio, decreased as
HIV-related disease progressed, as manifested by decreasing CD4 cell count
and increasing HIV RNA (viral load). Since TNF-alpha is an important
component of the innate immune system and is produced upon activation of
Toll-like receptor (TLR) pathways, we hypothesized that the mechanism
associated with deficient TNF-alpha production in the lung involved altered
TLR expression or a deficit in the TLR signaling cascade. We found decreased
Toll-like receptor 1 (TLR1) and TLR4 surface expression in HIV-infected U1
monocytic cells compared to the uninfected parental U937 cell line and
decreased TLR message in alveolar macrophages (AMs) from HIV-positive
subjects. In addition, stimulation with TLR1/2 ligand (Pam(3)Cys) or TLR4
ligand (lipopolysaccharide) resulted in decreased intracellular
phosphorylated extracellular signal-regulated kinase and subsequent
decreased transcription and expression of TNF-alpha in U1 cells compared to
U937 cells. AMs from HIV-positive subjects also showed decreased TNF-alpha
production in response to these TLR2 and TLR4 ligands. We postulate that HIV
infection alters expression of TLRs with subsequent changes in mitogen-activated
protein kinase signaling and cytokine production that ultimately leads to
deficiencies of innate immune responses that predispose HIV-positive
subjects to infection.
7)
http://www.jimmunol.org/cgi/content/full/170/1/508
Prior exposure to LPS both in vitro and in vivo can lead to
desensitization of immune cells to subsequent challenge
with LPS, a phenomenon that has been referred to as
"endotoxin tolerance."
Induction of in vitro reprogramming by
Toll-like receptor (TLR)2 and TLR4 agonists in murine macrophages:
effects of TLR "homotolerance" versus "heterotolerance" on NF-kappa
B signaling pathway components.
Department of Microbiology and Immunology,
University of Maryland, Baltimore, MD 21201, USA.
In this study, tolerance induction by
preexposure of murine macrophages to Toll-like receptor (TLR)2 and
TLR4 agonists was revisited, focusing on the major signaling
components associated with NF-kappaB activation. Pretreatment of
macrophages with a pure TLR4 agonist (protein-free Escherichia coli
(Ec) LPS) or with TLR2 agonists (Porphyromonas gingivalis LPS or
synthetic lipoprotein Pam3Cys) led to suppression of TNF-alpha
secretion, IL-1R-associated kinase-1, and IkappaB kinase (IKK)
kinase activities, c-jun N-terminal kinase, and extracellular
signal-regulated kinase phosphorylation, and to suppression of NF-kappaB
DNA binding and transactivation upon challenge with the same agonist
(TLR4 or TLR2 "homotolerance," respectively). Despite inhibited NF-kappaB
DNA binding, increased levels of nuclear NF-kappaB were detected in
agonist-pretreated macrophages. For all the intermediate signaling
elements, heterotolerance was weaker than TLR4 or TLR2 homotolerance
with the exception of IKK kinase activity. IKK kinase activity was
unperturbed in heterotolerance. TNF-alpha secretion was also
suppressed in P. gingivalis LPS-pretreated, Ec LPS-challenged cells,
but not vice versa, while Pam3Cys and Ec LPS did not induce a state
of cross-tolerance at the level of TNF-alpha. Experiments designed
to elucidate novel mechanisms of NF-kappaB inhibition in tolerized
cells revealed the potential contribution of IkappaBepsilon and
IkappaBxi inhibitory proteins and the necessity of TLR4 engagement
for induction of tolerance to Toll receptor-IL-1R domain-containing
adapter protein/MyD88-adapter-like-dependent gene expression.
Collectively, these data demonstrate that induction of homotolerance
affects a broader spectrum of signaling components than in
heterotolerance, with selective modulation of specific elements
within the NF-kappaB signaling pathway.
8) Lipid-associated membrane proteins
of Mycoplasma fermentans and M.
penetrans activate human immunodeficiency virus
long-terminal repeats through Toll-like receptors
Takashi Shimizu, Yutaka Kida, and Koichi KuwanoDepartment of Bacteriology, Kurume University School of
Medicine, Kurume, Japan
Immunology. 2004 September; 113(1):
121–129.
Mycoplasmas are known to enhance human immunodeficiency virus
(HIV) replication, and mycoplasma-derived lipid extracts have been
reported to activate nuclear factor-κB (NF-κB) through Toll-like
receptors (TLRs). In this study, we examined the involvement of TLRs
in the activation of HIV long-terminal repeats (LTR) by mycoplasma
and their active components responsible for the TLR activation.
Lipid-associated membrane proteins (LAMPs) from two species of
mycoplasma (Mycoplasma fermentans and
M. penetrans) that are associated with acquired
immune-deficiency syndrome (AIDS), were found to activate HIV LTRs
in a human monocytic cell line, THP-1. NF-κB deletion from the LTR
resulted in inhibition of the activation. The LTR activation by
M. fermentans LAMPs was inhibited by a dominant negative
(DN) construct of TLR1 and TLR6, whereas HIV LTR activation by
M. penetrans LAMPs was inhibited by DN TLR1, but not by
DN TLR6. These results indicate that the activation of HIV LTRs by
M. fermentans and
M. penetrans LAMPs
is dependent on NF-κB, and that the activation of HIV LTR by
M. fermentans LAMPs is mediated through TLR1, TLR2 and
TLR6. In contrast, the LTR activation by M. penetrans
LAMPs is carried out through TLR1 and TLR2, but not TLR6.
Subsequently, the active component of M. penetrans
and M. fermentans LAMPs was purified by
reverse-phase high-performance liquid chromatography (HPLC).
Interestingly, the purified lipoprotein of M. penetrans
LAMPs (LPMp) was able to activate NF-κB through TLR1 and TLR2. On
the other hand, the activation of NF-κB by purified lipoprotein of
M. fermentans LAMPs (LPMf) was mediated through TLR2
and TLR6, but not TLR1.Keywords: HIV, lipoprotein, mycoplasma, Toll-like
receptor
In mycoplasmas, acylated proteins are abundant cell-surface
antigens, and many putative lipoprotein-encoding genes have been
identified in the sequenced mycoplasma genomes.49,50
It is, at present, controversial as to whether or not mycoplasmas
have triacylated lipoprotein. Chemically identified lipoproteins
from M. fermentans,44M.
hyorhinis,51M.
salivarium46
and M. gallisepticum52
are not N-acylated, nor has an N-acyltransferase gene been
found in M. pneumoniae,53M.
genitalium54
or M. penetrans55
genomes. To date, the presence of proteins with N-acyltransferase
activity has not been clearly established. However, the study on the
ratio of N-amide and O-ester bonds in M.
gallisepticum and M. mycoides may indicate the
presence of diacylated and triacylated lipoproteins.56
The resistance to Edoman degradation of proteins from M.
mycoides also indicates the presence of N-acylation.50
In this study, we found that the lipoprotein separated from M.
penetrans induced NF-κB through TLR1 and TLR2. Triacylated
lipoproteins, such as Pam3-CSK4, have been reported to be recognized
by TLR1 and TLR2,43
whereas diacylated lipoproteins, such as MALP-2, have been shown to
be recognized by TLR2 and TLR6.42
Interestingly, synthetically triacylated MALP-2,
N-palamitoyl-MALP-2, was not recognized by TLR6.57
These findings may indicate the existence of triacylated
lipoproteins in mycoplasma species.
9) BRUCELLA and Pam3Cys
causing immune suppression:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=17984211
Copyright © 2008, American Society for Microbiology
Brucella abortus
Inhibits Major Histocompatibility Complex Class II Expression
and Antigen Processing through Interleukin-6 Secretion via
Toll-Like Receptor 2
Infect Immun.
2008 January;
76(1):
250–262.
The strategies that allow
Brucella
abortus to survive inside macrophages for prolonged periods
and to avoid the immunological surveillance of major
histocompatibility complex class II (MHC-II)-restricted gamma
interferon (IFN-γ)-producing CD4+ T lymphocytes are
poorly understood. We report here that infection of THP-1 cells with
B. abortus inhibited expression of MHC-II molecules
and antigen (Ag) processing. Heat-killed B. abortus
(HKBA) also induced both these phenomena, indicating the
independence of bacterial viability and involvement of a structural
component of the bacterium. Accordingly, outer membrane protein 19
(Omp19), a prototypical B. abortus lipoprotein,
inhibited both MHC-II expression and Ag processing to the same
extent as HKBA. Moreover, a synthetic lipohexapeptide that mimics
the structure of the protein lipid moiety also inhibited MHC-II
expression, indicating that any Brucella lipoprotein
could down-modulate MHC-II expression and Ag processing. Inhibition
of MHC-II expression and Ag processing by either HKBA or lipidated
Omp19 (L-Omp19) depended on Toll-like receptor 2 and was mediated by
interleukin-6. HKBA or L-Omp19 also inhibited MHC-II expression and
Ag processing of human monocytes. In addition, exposure to the
synthetic lipohexapeptide inhibited Ag-specific T-cell proliferation
and IFN-γ production of peripheral blood mononuclear cells from
Brucella-infected patients. Together, these results
indicate that there is a mechanism by which B. abortus
may prevent recognition by T cells to evade host immunity and
establish a chronic infection.
TUBERCULOSIS (FUNGAL) VACCINES
FAILURES:
http://www.ncbi.nlm.nih.gov/pubmed/10792376
The 19-kD antigen and
protective immunity in a murine model of tuberculosis.
Yeremeev VV, Lyadova IV,
Nikonenko BV, Apt AS, Abou-Zeid C, Inwald J, Young DB.
"The
19-kD antigen is a cell wall-associated lipoprotein present in
Mycobacterium tuberculosis and in bacille Calmette-Guérin (BCG)
vaccine strains. Expression of the 19-kD antigen as a
recombinant protein in two saprophytic mycobacteria-M. vaccae
and M. smegmatis-resulted in abrogation of their ability to
confer protection against M. tuberculosis in a murine challenge
model, and in their ability to prime a DTH response to
cross-reactive mycobacterial antigens. Induction of an immune
response to the 19-kD antigen by an alternative approach of DNA
vaccination had no effect on subsequent M. tuberculosis
challenge. These results are consistent with a model in which
the presence of the 19-kD protein has a detrimental effect on
the efficacy of vaccination with live mycobacteria. Targeted
inactivation of genes encoding selected antigens represents a
potential route towards development of improved vaccine
candidates."
http://www.ncbi.nlm.nih.gov/pubmed/11179309
Mycobacterium tuberculosis
19-kilodalton lipoprotein inhibits Mycobacterium smegmatis-induced
cytokine production by human macrophages in vitro.
Post FA, Manca C, Neyrolles O, Ryffel B, Young DB, Kaplan G.
Vaccination of mice with
Mycobacterium vaccae or M. smegmatis induces some protection
against M. tuberculosis challenge. The 19-kDa lipoprotein of M.
tuberculosis, expressed in M. vaccae or M. smegmatis (M.
smeg19kDa), abrogates this protective immunity. To investigate the mechanism of this suppression of immunity, human
monocyte-derived macrophages (MDM) were infected with M.
smeg19kDa. Infection resulted in reduced production of tumor
necrosis factor alpha (TNF-alpha) (P < 0.01), interleukin-12
(IL-12) (P < 0.05), IL-6 (P < 0.05), and IL-10 (P < 0.05),
compared to infection with M. smegmatis vector (M. smegV).
Infection with M. smeg19kDa and with M. smegV had no
differential effect on expression of costimulatory molecules on
MDM, nor did it affect the proliferation of presensitized T
cells cocultured with infected MDM. When MDM were infected with
M. smegmatis expressing mutated forms of the 19-kDa lipoprotein,
including non-O-glycosylated (M. smeg19NOG), nonsecreted (M.
smeg19NS), and nonacylated (M. smeg19NA) variants, the reduced
production of TNF-alpha or IL-12 was not observed. When the
purified 19-kDa lipoprotein was added directly to cultures of
infected monocytes, there was little effect on either induction
of cytokine production or its inhibition. Thus, the
immunosuppressive effect is dependent on glycosylated and
acylated 19-kDa lipoprotein present in the phagosome containing
the mycobacterium. These results suggest that the diminished
protection against challenge with M. tuberculosis seen in mice
vaccinated with M. smegmatis expressing the 19-kDa lipoprotein
is the result of reduced TNF-alpha and IL-12 production,
possibly leading to reduced induction of T-cell activation."
http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=12761093
- Infect Immun. 2003
Jun;71(6):3146-54.
Related Articles,
Links
-
The Mycobacterium tuberculosis recombinant
27-kilodalton lipoprotein induces a strong Th1-type immune
response deleterious to protection.
Hovav AH, Mullerad J, Davidovitch L, Fishman Y, Bigi F, Cataldi
A, Bercovier H.
Department of Clinical Microbiology, Faculty of Medicine, The
Hebrew University, Jerusalem, Israel.
Th1 immune response is essential in the protection against
mycobacterial intracellular pathogens. Lipoproteins trigger both
humoral and cellular immune responses and may be candidate
protective antigens. We studied in BALB/c mice the
immunogenicity and the protection offered by the recombinant
27-kDa Mycobacterium tuberculosis lipoprotein and the
corresponding DNA vaccine. Immunization with the 27-kDa antigen
resulted in high titers of immunoglobulin G1 (IgG1) and IgG2a
with a typical Th1 profile and a strong delayed hypersensitivity
response. A strong proliferation response was observed in
splenocytes, and significant nitric oxide production and gamma
interferon secretion but not interleukin 10 secretion were
measured. Based on these criteria, the 27-kDa antigen induced a
typical Th1-type immune response thought to be necessary for
protection. Surprisingly, in 27-kDa-vaccinated mice (protein or
DNA vaccines) challenged by M. tuberculosis H37Rv or BCG
strains, there was a significant increase in the numbers of
CFU in the spleen compared to that for control groups.
Furthermore, the protection provided by BCG or other
mycobacterial antigens was completely abolished once the 27-kDa
antigen was added to the vaccine preparations. This study
indicates that the 27-kDa antigen has an adverse effect on the
protection afforded by recognized vaccines. We are currently
studying how the 27-kDa antigen modulates the mouse immune
response.
|